Refine by
Oncology S New Drug Application Articles & Analysis
13 news found
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. Oncovita and the Institut Pasteur have already been working together for several years on the construction and development of ...
ByOncoVITA
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of minimally-invasive cryoablation technology, the ProSense System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it hosted three key ProSense System events at the European Conference on Interventional Oncology (ECIO) from April 24 to 27, ...
Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for futibatinib in the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) harboringFGFR2 gene rearrangements, including gene fusions. ...
Gauden served as Product Leader for oncology molecular imaging at GE Healthcare, with business responsibility for the product portfolio, licensing, product development and strategic marketing activities across a range of developmental PET drugs. ...
ImpediMed Limited (ASX.IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximize patient health is pleased to announce an abstract comparing concurrent measures using ImpediMed’s SOZO® Digital Health Platform and dual x-ray absorptiometry (DXA) for assessing in bone mineral content in cancer patients was accepted for ...
Today, Novosanis has launched its novel solution for oncology research applications. Together with our sister company DNA Genotek, we have developed a novel stabilization chemistry, UAS, for the preservation of extracellular vesicle (EV) RNA, and cell-free DNA (cfDNA) in urine, collected with Colli-Pee. Novosanis hereby offers a solution for applications in the field of oncology research and ...
To support clinical research needs using next-generation sequencing (NGS), Thermo Fisher Scientific today announced it is accepting new submissions for its Oncomine Clinical Research Grant. The latest call for proposals aims to provide funding for clinical research programs that leverage NGS in solid tumors and hematology-oncology applications. The Oncomine Clinical Research Grant awards ...
City of Hope®, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use ...
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, today announced the expansion of its leadership team with the appointment of a Chief Scientific Officer and two additional Board members. ...
Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. In addition, GRAIL stockholders will receive future payments representing a tiered single digit ...
As countries begin to ease restrictions and allow some businesses to reopen, contact tracing and epidemiological studies will be critical to understand resurgence of potential COVID-19 outbreaks. Scientists not only need to know who is infected, they also need to rapidly identify which strain of the virus is spreading. To expedite such analysis, Thermo Fisher Scientific has now optimized its Ion ...
Imaxio, a biotech company specialized in immunology, announces today the execution of a collaboration agreement with Centre Léon Bérard, and the award of a grant, as part of the program “Proof of Concept CLARA” from the Cancéropôle Lyon Auvergne-Rhône-Alpes (CLARA), to finance the ORPhEE project. The ORPhEE project, “non-antigen specific ...
Biopticon Corporation reaches milestone in market adoption of their innovative Tumor Management System for preclinical oncology studies. Innovative instrument and software create revolutionary system to improve data, work-flow and results from in vivo cancer models Princeton, NJ Biopticon today announced that it had met its first milestone for customer adoption of the revolutionary ...